Reviews/COPD Pharmacotherapy/Triple therapy mortality benefit
Triple Therapy · COPD-TT-02 · v2
The question is whether adding a third inhaled drug (triple therapy) helps COPD patients live longer. One large trial [1] found fewer deaths with triple therapy, but only when compared against a specific two-drug combination that did not contain a steroid, and not when compared against the two-drug combination that did contain a steroid. A very large study of real-world patients [2] actually found more deaths with triple therapy overall, and a second real-world study [4] found no overall difference in deaths. So the single positive result comes from one comparison in one trial and points the opposite way to the everyday-practice data. The panel treated the survival claim as unqualified for all COPD and found the evidence here too divided and too comparator-specific to support it.
The only positive primary result is the ETHOS trial [1], where triple BGF 320 lowered death risk versus the non-steroid dual GFF (hazard ratio 0.51; 95% CI 0.33-0.80; P = 0.0035) but not versus the steroid-containing dual BFF (hazard ratio 0.72; 95% CI 0.44-1.16; P = 0.1721). The largest real-world cohort [2], with 117,729 triple and 26,666 dual new-users, found all-cause mortality higher with triple therapy (HR 1.17; 95% CI 1.04-1.31). A retrospective post-hospitalisation cohort of 500 patients [4] found no overall difference (aHR 0.88; 95% CI 0.57-1.36), with benefit only in high-risk strata such as those with two or more prior exacerbations. The directions are therefore contradictory, and the one favourable signal is tied to a single agent, dose and comparator. The contested point: The division is whether ETHOS [1] shows benefit from triple therapy or harm from steroid withdrawal in its non-steroid comparator arm: the reduction reaches significance only against GFF, not against the steroid-containing BFF. Suissa [2] attributes the trial signal to ICS withdrawal at randomization and reports elevated mortality with triple therapy in routine practice, so trial and real-world data point in opposite directions.
All 11 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from COPD Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
ETHOS mortality reduction is significant only versus GFF (non-ICS dual) and NOT versus BFF (ICS-containing dual, HR 0.72 NS); Suisso attributes the trial signal to ICS withdrawal at randomization in the comparator arm, so the effect may be harm-from-withdrawal in the control rather than benefit from triple therapy.
The largest real-world dataset [2] shows all-cause mortality is higher with triple therapy overall (HR 1.17, 1.04-1.31), directly contradicting an unqualified mortality-reduction claim.
Where it remains uncertain. The largest real-world cohort [2] found mortality higher with triple therapy (HR 1.17; 95% CI 1.04-1.31) and a post-hospitalisation cohort [4] found no overall effect (aHR 0.88; 95% CI 0.57-1.36).
Aleatory
Cardiovascular deaths occurred in 0.5-1.4% of ETHOS arms [1], so absolute event counts are small and wide confidence intervals (e.g. BGF 320 vs BFF 0.44-1.16) reflect chance variation.
Epistemic
Whether ETHOS [1] reflects benefit from triple therapy or harm from ICS withdrawal in the dual comparator [2] cannot be settled by the corpus.
Inferential
The positive estimate [1] is confined to BGF 320 versus the non-steroid dual; extending it to all triple regimens and all COPD is an inference the corpus does not support.
The load-bearing papers from a corpus of 11, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
RCT mortality reduction present only against the non-ICS dual comparator, not against the ICS-containing dual
“risk of death with BGF 320 was significantly lower than GFF (hazard ratio, 0.51; 95% confidence interval, 0.33-0.80; unadjusted P = 0.0035). There were no significant differences in mortality when comparing BGF 320 with BFF (hazard ratio, 0.72; 95% confidence interval, 0.44-1.16; P = 0.1721)”
Panel auditInternal validity: high · scope of inference: Moderate-to-very-severe COPD with prior exacerbation history; triple versus specific dual regimens over 52 weeks.Key limitations: benefit significant only vs LAMA/LABA, not vs ICS/LABA · secondary endpoint · comparator ICS withdrawal possible
Independent cohort shows no overall mortality benefit; benefit confined to high-risk subgroups
Panel auditInternal validity: medium · scope of inference: Patients hospitalised for severe COPD exacerbation at one tertiary hospital; three-year mortality by triple-therapy receipt.Key limitations: observational single-centre · wide confidence interval · subgroup findings exploratory
Real-world data contradict the claim, showing elevated mortality with triple therapy overall
“The adjusted hazard ratio (HR) of all-cause mortality with LAMA-LABA-ICS compared with LAMA-LABA was 1.17 (95% CI: 1.04-1.31)”
Panel auditInternal validity: medium · scope of inference: COPD patients aged 50+ in UK primary-care practice initiating triple vs dual therapy, one-year follow-up.Key limitations: observational design · confounding by indication · effect reversed in asthma/≥2-exacerbation subgroups
3 of 11 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A single comparator-dependent RCT signal, plausibly a withdrawal artifact and contradicted by real-world cohort data, cannot carry an unqualified all-COPD mortality-reduction claim.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Triple versus steroid-containing dual on mortality. ETHOS showed no significant survival difference versus BFF (HR 0.72; 95% CI 0.44-1.16) [1]; the benefit is only against the non-steroid dual, leaving the key comparison underpowered. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An adequately powered RCT comparing triple therapy against an ICS-containing dual with all-cause mortality as a primary endpoint and no ICS withdrawal at randomization.
Open question: Does triple therapy reduce all-cause mortality when compared against an ICS-containing dual, rather than a non-steroid dual? Why it is still open: ETHOS was significant only versus GFF, not versus BFF (HR 0.72; 95% CI 0.44-1.16; P = 0.1721) [1].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19